Illumine Investment Management LLC Acquires Shares of 2,990 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Illumine Investment Management LLC acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 4th quarter, Holdings Channel reports. The fund acquired 2,990 shares of the biopharmaceutical company’s stock, valued at approximately $2,130,000. Regeneron Pharmaceuticals comprises approximately 1.8% of Illumine Investment Management LLC’s investment portfolio, making the stock its 20th largest position.

Several other large investors also recently bought and sold shares of the stock. Nvwm LLC boosted its stake in Regeneron Pharmaceuticals by 1.4% in the third quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock valued at $1,039,000 after acquiring an additional 14 shares in the last quarter. Howe & Rusling Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 3.4% during the third quarter. Howe & Rusling Inc. now owns 462 shares of the biopharmaceutical company’s stock worth $486,000 after buying an additional 15 shares during the period. Willner & Heller LLC boosted its stake in shares of Regeneron Pharmaceuticals by 3.9% during the fourth quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company’s stock worth $284,000 after buying an additional 15 shares during the period. OLD Second National Bank of Aurora boosted its stake in shares of Regeneron Pharmaceuticals by 0.5% during the fourth quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company’s stock worth $2,025,000 after buying an additional 15 shares during the period. Finally, SteelPeak Wealth LLC raised its holdings in Regeneron Pharmaceuticals by 1.5% during the third quarter. SteelPeak Wealth LLC now owns 1,108 shares of the biopharmaceutical company’s stock worth $1,165,000 after purchasing an additional 16 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.6 %

Shares of REGN stock opened at $702.78 on Friday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $642.00 and a 12-month high of $1,211.20. The company has a market capitalization of $76.83 billion, a P/E ratio of 18.36, a P/E/G ratio of 2.34 and a beta of 0.08. The firm has a 50-day moving average price of $698.57 and a 200 day moving average price of $873.11. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period last year, the firm posted $11.86 EPS. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.50%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the stock. TD Cowen dropped their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research note on Tuesday, February 4th. Royal Bank of Canada decreased their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Piper Sandler decreased their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a report on Monday, January 27th. Wells Fargo & Company decreased their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. Finally, Truist Financial reduced their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.